跳转到主要内容
搜索

Impact of Target-mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software